Hematologic Malignancies
180
31
36
89
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
41 trials with published results (23%)
Research Maturity
89 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
11.1%
20 terminated out of 180 trials
81.7%
-4.9% vs benchmark
4%
8 trials in Phase 3/4
46%
41 of 89 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 89 completed trials
Clinical Trials (180)
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
Rutgers University Study of the Genetics of Blood Cancers
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
IVIG for Infection Prevention After CAR-T-Cell Therapy
Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia